According to a securities filing released on Monday, Kevin Tang, an acquisition specialist in the biotech sector, is solidifying his control over Aurinia Pharmaceuticals. The company's Chief Executive Officer and its core C-suite management team have all been replaced, marking a significant reshuffle in corporate leadership.
As Chairman of Aurinia's board, Kevin Tang has directly appointed himself as the new CEO. Simultaneously, executives from his firm, Tang Capital Management, have been installed in key roles: Ryan Cole as Chief Operating Officer and Michael Hearne as Chief Financial Officer. Thomas Wei, a Managing Director at Tang Capital, has been appointed Chief Scientific Officer. These personnel changes have been disclosed in filings with the U.S. Securities and Exchange Commission and related press releases.
As part of this restructuring, Aurinia's former management team was collectively dismissed last Friday. This group included former CEO Peter Greenleaf, former COO Matthew Donley, former CFO Joseph Miller, and Chief Medical Officer Gregory Keenan.
This is not the first instance of executive turmoil at Aurinia. The company's core business involves the development and sale of a lupus drug. However, after terminating most of its research projects in 2024, the company's development pipeline was reduced to a foundational level, raising concerns among investors about its future prospects.
Kevin Tang is a well-known activist investor with a history of initiating acquisitions. In 2024, amid Aurinia's research setbacks and its failure to find a suitable acquirer, discontent grew among investors. Tang capitalized on this opportunity to join the company's board. At that time, former CEO Peter Greenleaf had offered his resignation but was persuaded to stay by the board, yet he ultimately could not avoid dismissal.
Notably, Aurinia has recently been involved in controversy related to the FDA. Last September, CDER Director George Tidmarsh publicly singled out Aurinia in a since-deleted social media post, questioning the efficacy of its lupus drug, Lupkynis. He stated that despite the drug receiving accelerated FDA approval in 2021 and full approval in 2024, there was no current evidence demonstrating direct clinical benefits for patients.
Following this incident, past connections between George Tidmarsh and Kevin Tang came to light. Aurinia subsequently filed a lawsuit against the FDA official, accusing him of making "false and defamatory statements." The company alleged that Tidmarsh targeted the firm due to a long-standing personal grievance with Kevin Tang. The two had previously worked together at La Jolla Pharmaceutical, where Tang had pushed for the removal of Tidmarsh, who was then CEO. Aurinia's lawsuit claims Tidmarsh used his position at the FDA to seek retaliation.
George Tidmarsh resigned from the FDA last November and has stated he will vigorously defend against the lawsuit.
Comments